Literature DB >> 12138171

Molecular basis of scrapie strain glycoform variation.

Ina Vorberg1, Suzette A Priola.   

Abstract

Transmissible spongiform encephalopathies (TSE) are characterized by the conversion of a protease-sensitive host glycoprotein, prion protein or PrP-sen, to a protease-resistant form (PrP-res). PrP-res molecules that accumulate in the brain and lymphoreticular system of the host consist of three differentially glycosylated forms. Analysis of the relative amounts of the PrP-res glycoforms has been used to discriminate TSE strains and has become increasingly important in the differential diagnosis of human TSEs. However, the molecular basis of PrP-res glycoform variation between different TSE agents is unknown. Here we report that PrP-res itself can dictate strain-specific PrP-res glycoforms. The final PrP-res glycoform pattern, however, can be influenced by the cell and significantly altered by subtle changes in the glycosylation state of PrP-sen. Thus, strain-specific PrP-res glycosylation profiles are likely the consequence of a complex interaction between PrP-res, PrP-sen, and the cell and may indicate the cellular compartment in which the strain-specific formation of PrP-res occurs.

Entities:  

Mesh:

Substances:

Year:  2002        PMID: 12138171     DOI: 10.1074/jbc.M206865200

Source DB:  PubMed          Journal:  J Biol Chem        ISSN: 0021-9258            Impact factor:   5.157


  27 in total

1.  Autocatalytic self-propagation of misfolded prion protein.

Authors:  Jan Bieschke; Petra Weber; Nikolaus Sarafoff; Michael Beekes; Armin Giese; Hans Kretzschmar
Journal:  Proc Natl Acad Sci U S A       Date:  2004-08-05       Impact factor: 11.205

2.  Glycosylation-related genes are variably expressed depending on the differentiation state of a bioaminergic neuronal cell line: implication for the cellular prion protein.

Authors:  Myriam Ermonval; Daniel Petit; Aurélien Le Duc; Odile Kellermann; Paul-François Gallet
Journal:  Glycoconj J       Date:  2008-10-21       Impact factor: 2.916

3.  Acute cellular uptake of abnormal prion protein is cell type and scrapie-strain independent.

Authors:  Christopher S Greil; Ina M Vorberg; Anne E Ward; Kimberly D Meade-White; David A Harris; Suzette A Priola
Journal:  Virology       Date:  2008-08-08       Impact factor: 3.616

4.  A specific population of abnormal prion protein aggregates is preferentially taken up by cells and disaggregated in a strain-dependent manner.

Authors:  Young Pyo Choi; Suzette A Priola
Journal:  J Virol       Date:  2013-08-21       Impact factor: 5.103

5.  Disease phenotype in sheep after infection with cloned murine scrapie strains.

Authors:  Silvia Sisó; Francesca Chianini; Sam L Eaton; Janey Witz; Scott Hamilton; Stuart Martin; Jeanie Finlayson; Yvonne Pang; Paula Stewart; Philip Steele; Mark P Dagleish; Wilfred Goldmann; Hugh W Reid; Martin Jeffrey; Lorenzo González
Journal:  Prion       Date:  2012-04-01       Impact factor: 3.931

6.  Separation of native prion protein (PrP) glycoforms by copper-binding using immobilized metal affinity chromatography (IMAC).

Authors:  Henrik Müller; Alexander Strom; Gerhard Hunsmann; Andreas W Stuke
Journal:  Biochem J       Date:  2005-05-15       Impact factor: 3.857

7.  Prion infection of epithelial Rov cells is a polarized event.

Authors:  Sophie Paquet; Elifsu Sabuncu; Jean-Louis Delaunay; Hubert Laude; Didier Vilette
Journal:  J Virol       Date:  2004-07       Impact factor: 5.103

Review 8.  The role of the prion protein membrane anchor in prion infection.

Authors:  Suzette A Priola; Kristin L McNally
Journal:  Prion       Date:  2009-07-07       Impact factor: 3.931

9.  Prion strain discrimination in cell culture: the cell panel assay.

Authors:  Sukhvir P Mahal; Christopher A Baker; Cheryl A Demczyk; Emery W Smith; Christian Julius; Charles Weissmann
Journal:  Proc Natl Acad Sci U S A       Date:  2007-12-11       Impact factor: 11.205

10.  Species and strain glycosylation patterns of PrPSc.

Authors:  Konstantinos Xanthopoulos; Magdalini Polymenidou; Sue J Bellworthy; Sylvie L Benestad; Theodoros Sklaviadis
Journal:  PLoS One       Date:  2009-05-20       Impact factor: 3.240

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.